Helixgate

Helixgate

Uncategorized

Autism Risk Genes Largely Shared Across Global Populations

Published

on

Over the past decade, scientists have identified numerous genetic variants that confer substantial risk for autism and other neurodevelopmental disorders. However, most of these discoveries were made in cohorts composed predominantly of individuals of European ancestry. This leaves open the question of whether autism’s genetic underpinnings differ across populations. This knowledge gap has contributed to disparities in genetic testing, including higher rates of inconclusive results among non-European individuals due to limited reference data.

To address this, the Genomics of Autism in Latin American Ancestries (GALA) Consortium presents the largest sequencing study of autism in Latin American individuals and demonstrates that genes associated with autism risk are largely the same across people of different ancestries. The team identified 35 genome-wide significant autism-associated genes, with “substantial overlap with findings from European cohorts, and highly constrained genes showing consistent signal across populations.”

The findings provide strong evidence that the genetic architecture of autism is consistent across diverse populations and underscore the importance of expanding genetic research beyond individuals of European ancestry. The work also “provides support for emerging and established autism genes and for the utility of genetic testing approaches for deleterious variants in individuals from diverse backgrounds.”

This work is published in Nature Medicine in the paper, “Deleterious coding variation associated with autism is shared across ancestries.

autism map
Map of GALA collection sites across the Americas. [Marina Natividad Avila, MSc]

The research team analyzed exome and genome sequencing data from more than 15,000 Latin American individuals across North, Central, and South America, including approximately 4,700 individuals diagnosed with autism. Latin American populations represent the largest recently mixed-ancestry group globally, with heritage that frequently includes Indigenous American, West African, and European origins. This rich genetic diversity provides a powerful opportunity to refine gene-disease associations, which can improve health outcomes for all populations.

The study examined more than 18,000 genes for enrichment of rare, deleterious coding variants. Consistent with prior research, rare, deleterious variants in highly conserved genes—genes that remain similar across species and populations over long periods of time—were disproportionately observed in individuals with autism. Researchers identified 35 genes significantly associated with autism in the Latin American cohort. These genes showed extensive overlap with those previously identified in genome-wide studies of individuals of European ancestry. The findings also provide support for several recently identified “emerging” autism-associated genes.

“Our results indicate that the core genetic architecture of autism is shared across ancestries,” said study senior author Joseph D. Buxbaum, PhD, director of the Seaver Autism Center for Research and Treatment at Mount Sinai. “This suggests that the biology underlying autism is universal and reinforces the importance of ensuring that diverse populations are represented in genetic research.”

The study also evaluated widely used metrics that assess evolutionary conservation of genes, an important tool for prioritizing genes in clinical genetic analyses of neurodevelopmental disorders. The researchers found that these metrics, which were again largely derived from European-ancestry datasets, may overestimate conservation overall due to limited ancestral diversity in European populations. However, the metrics remain highly accurate for the most strongly conserved genes—including those most relevant to autism and other neurodevelopmental disorders.

The authors note that continued sequencing of diverse populations will further improve conservation metrics, particularly for less conserved genes, ultimately enhancing the accuracy of clinical genetic testing.

“These findings provide a road map for improving genetic diagnosis across ancestral groups,” said Buxbaum. “Expanding genomic research in underrepresented populations is essential to reducing health disparities and advancing precision medicine for autism and related conditions across all ancestral populations.”

The study’s results align with growing evidence that both rare and common genetic risk factors for complex disorders are shared across diverse populations. By demonstrating broad overlap in autism risk genes across ancestries, the research supports more inclusive approaches to genomic medicine and reinforces the universal biological foundations of autism.

The post Autism Risk Genes Largely Shared Across Global Populations appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

on

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

 

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading
Advertisement

Trending